Protective Effect of Conditioned Medium of Immortalized Human Stem Cells from Exfoliated Deciduous Teeth Against Hair Graying Caused by X-Ray Irradiation via Its Antioxidative Acti... by Yasuhiro Katahira, Eri Horio, Natsuki Yamaguchi, Jukito Sonoda, Miu Yamagishi, Satomi Miyakawa, Fumihiro Murakami, Hideaki Hasegawa, Izuru Mizoguchi, Takayuki Yoshimoto

“…Consistent with these in vivo results, SHED-CM significantly inhibited the cell death caused by X-ray irradiation in melanoma cell line B16F10 cells. Immunodepletion of HGF or VEGF in the SHED-CM revealed that this inhibition was due to suppression of the generation of reactive oxygen species, which was mainly mediated by HGF and probably VEGF. …”
Get full text

Integrative analysis of miRNA expression data reveals a minimal signature for tumour cells classification by Sabrina Napoletano, David Dannhauser, Paolo Antonio Netti, Filippo Causa

“…In this study, we present a comprehensive integrative approach that utilizes transcriptomic data from lung, breast, and melanoma cancer cell lines to identify specific expression patterns. …”
Get full text

Electrochemotherapy with bleomycin, oxaliplatin, or cisplatin in mouse tumor models, from tumor ablation to in situ vaccination by Katja Uršič Valentinuzzi, Katja Uršič Valentinuzzi, Urška Kamenšek, Urška Kamenšek, Simona Kranjc Brezar, Chloe Heranney, Chloe Heranney, Tilen Komel, Tilen Komel, Simon Buček, Simon Buček, Maja Čemažar, Maja Čemažar, Gregor Serša, Gregor Serša

“…By evaluating ECT’s potential for in situ vaccination, our goal was to pave the way for future advancements for its combination with emerging (immuno)therapies, leading to enhanced responses and outcomes.MethodsWe employed two mouse tumor models, the immunologically cold B16F10 melanoma and 4T1 mammary carcinoma, to explore both local and systemic (i.e., abscopal) antitumor effects following equieffective intratumoral ECT with BLM, OXA, and CDDP. …”
Get full text

Construction of an anaplastic thyroid cancer stratification signature to guide immune therapy selection and validation of the pivotal gene HLF through in vitro experiments by Li Pengping, Yin Kexin, Xie Yuwei, Sun Ke, Li Rongguo, Wang Zhenyu, Jin Haigang, Wang Shaowen, Huang Yuqing

“…This led to the creation of a refined signature for predicting ATC’s immune responsiveness to anti-PD1 therapy, which was further validated using thyroid cancer cohorts from TCGA and nine melanoma cohorts from clinical trials. Among the 12 genes, HLF stood out due to its strong association with various cancer hallmarks.DiscussionOur study revealed that HLF impedes ATC progression by down-regulating the epithelial-to-mesenchymal transition (EMT) pathway, reducing T cell exhaustion, and increasing sensitivity to sorafenib, as demonstrated through our in-vitro experiments.…”
Get full text

Immunosuppression and Outcomes in Patients with Cutaneous Squamous Cell Carcinoma of the Head and Neck by Doriana Iancu, Ana Fulga, Doina Vesa, Iuliu Fulga, Dana Tutunaru, Andrei Zenovia, Alin Ionut Piraianu, Elena Stamate, Corina Sterian, Florentin Dimofte, Mihail Alexandru Badea, Alin Laurentiu Tatu

“…Cutaneous squamous scell carcinoma (cSCC) is a frequent non-melanoma skin cancer that originates from keratinocytes with increased prevalence. cSCC can be either in situ, as in Bowen’s disease, or extended. …”
Get full text

Black posterior vitreous detachment: A 10-year historical cohort of pigmented uveal tumors by Vicktoria Vishnevskia-Dai, Hila Goldberg, Michael Ostrovsky, Ofira Zloto, Rachel Shemesh

“…The most prevalently associated ocular tumor was malignant choroidal melanoma (7/8; 87.5 %). A pigmentary PVD was observed on presentation in one case (1/8; 12.5 %); the remaining cases had pigmentary PVD documented during follow-up. …”
Get full text

CYFIP2: potential pancreatic cancer biomarker and immunotherapeutic target by Cong Xiao, Xiaojuan Zhang, Bobo Hou, Ping Wan, Zhenjun Cao, Xuefeng Rao

“…Results Bioinformatics analysis and in vitro experiments confirmed that CYFIP2 was differentially expressed in a variety of tumors and correlated with clinical stage, and could be used as a potential marker for evaluating the prognosis and immunotherapy of a variety of tumors, including KIRC (Kidney renal clear cell carcinoma), PAAD (Pancreatic adenocarcinoma), PAAD (Pancreatic adenocarcinoma), SKCM (Skin Cutaneous Melanoma), and UCEC (Uterine Corpus Endometrial Carcinoma).Mutations in the CYFIP2 gene and methylation indices can affect the prognosis of tumor patients. …”
Get full text

CHAT-S study protocol: A randomized controlled trial of a health insurance literacy education program for young adult cancer survivors by Mary Killela, Cindy A. Turner, Amy Chevrier, Monique Stefanou, Perla L. Vaca Lopez, Heydon K. Kaddas, Karely M. van Thiel Berghuijs, Echo L. Warner, Giselle K. Perez, Austin R. Waters, Douglas B. Fair, Richard E. Nelson, Mark A. Lewis, Elyse R. Park, Anne C. Kirchhoff

“…We will enroll 300 YA cancer survivors (n = 200 intervention; n = 100 usual care) diagnosed with breast, testicular, lymphoma, sarcoma, colorectal, melanoma, or thyroid cancer between the ages of 26 and 39, who have completed treatment in the past two years. …”
Get full text

Preclinical model for evaluating human TCRs against chimeric syngeneic tumors by Olivier Michielin, Philippe Guillaume, Melita Irving, Patrick Reichenbach, Vincent Zoete, Elise Gray-Gaillard, Evangelos Stefanidis, Aikaterini Semilietof, Julien Pujol, Alessia D'Esposito

“…We evaluated a variety of strategies to stably express A2Kb:NY on the surface of mouse tumor cell lines including B16 melanoma, ultimately achieving success with an SCT comprising human β2m fused by GS linkers to both the NY-peptide and to α1 of the HLA complex. …”
Get full text

Radiation to all macroscopic sites of tumor permits greater systemic antitumor response to in situ vaccination by Zachary S Morris, Paul M Sondel, Amy K Erbe, Alexander L Rakhmilevich, Amber M Bates, Peter M Carlson, Alexander A Pieper, Ravi B Patel, Jen Birstler, Joseph Grudzinski, Reinier Hernandez, Bryan P Bednarz, Jamey P Weichert, Arika S Feils, Matthew Rodriquez, Claire Sun, Ian Marsh

“…Given the immune-stimulatory capacity of radiation therapy (RT), we hypothesized that delivering RT to all sites of disease would augment systemic antitumor responses to ISV.Methods We used a syngeneic B78 murine melanoma model consisting of a ‘primary’ flank tumor and a contralateral smaller ‘secondary’ flank tumor, treated with 12 Gy EBRT and intratumoral IC immunotherapy to the primary and additional EBRT to the secondary tumor. …”
Get full text

Transition metal-based MOFs for Fenton-like photocatalytic degradation of organic pollutants: Performance, stability, and biocompatibility by S.M. Tikhanova, Yu.A. Tishchenko, E.Yu. Stovpiaga, M. Timofeeva, D.V. Lipin, S.A. Povarov, V.A. Milichko, A.S. Timin, S.A. Shipilovskikh, V.I. Popkov

“…In vitro studies conducted on human monocytes (THP-1), murine embryonic fibroblasts (MEF-NF), breast cancer cells (4T1), melanoma cells (B16-F10), and colorectal cancer cells (CT26) demonstrated high biocompatibility of the developed MOFs. …”
Get full text

Signatures of H3K4me3 modification predict cancer immunotherapy response and identify a new immune checkpoint-SLAMF9 by Tao Fan, Chu Xiao, Ziqin Deng, Shuofeng Li, He Tian, Yujia Zheng, Bo Zheng, Chunxiang Li, Jie He

“…Importantly, this risk-score system showed satisfactory predictive performance for the ICB therapy responses of patients suffering from several cancer types, and we identified that SLAMF9 was one of the immunosuppressive phenotype and immunotherapy resistance-determined genes of H3K4me3-RS. The mice melanoma model showed Slamf9 knockdown remarkably restrained cancer progression and enhanced the efficacy of anti-CTLA-4 and anti-PD-L1 therapies by elevating CD8 + T cell infiltration. …”
Get full text

(<i>E</i>)-1-(3-(3-Hydroxy-4-Methoxyphenyl)-1-(3,4,5-Trimethoxyphenyl)allyl)-1<i>H</i>-1,2,4-Triazole and Related Compounds: Their Synthesis and Biological Evaluation as Novel Anti... by Gloria Ana, Azizah M. Malebari, Sara Noorani, Darren Fayne, Niamh M. O’Boyle, Daniela M. Zisterer, Elisangela Flavia Pimentel, Denise Coutinho Endringer, Mary J. Meegan

“…In addition, compound <b>22b</b> demonstrated potent activity in the sub-micromolar range against the NCI 60 cancer cell line panel including prostate, melanoma, colon, leukemia, and non-small cell lung cancers. …”
Get full text

Umbilical Cord Mesenchymal Stromal Cell-Derived Small Extracellular Vesicles Modulate Skin Matrix Synthesis and Pigmentation by Kee LT, Foo JB, How CW, Nur Azurah AG, Chan HH, Mohd Yunus MH, Ng SN, Ng MH, Law JX

“…Additionally, the effects of UC-MSC-sEVs on the proliferation, melanin content, and tyrosinase (TYR) activity of human melanoma cells (MNT-1) were examined. Furthermore, ex vivo models were employed to evaluate the skin permeation of PKH26-labelled UC-MSC-sEVs.Results: The findings indicated that a high concentration of UC-MSC-sEVs positively influenced the proliferation of HDF. …”
Get full text

Utilization of primary tumor samples for cancer neoantigen discovery by Yong Li, Steven A Rosenberg, Paul Robbins, Billel Gasmi, Todd D Prickett, Jared J Gartner, Devikala Gurusamy, Stephanie L Goff, Vid Leko, Victoria Hill, Frank J Lowery, Bradley Sinclair White, Sivasish Sindiri, Maria Parkhust, Noam Levin, Eric Groh, Shoshana T Levi, Amy R Copeland, Sanghyun Peter Kim

“…Background The use of tumor-infiltrating T lymphocytes (TIL) that recognize cancer neoantigens has led to lasting remissions in metastatic melanoma and certain cases of metastatic epithelial cancer. …”
Get full text

Therapeutic applications of artemisinin in ophthalmic diseases by Hao Sun, Ping Zhao, Lianghui Zhao, Zhizhong Zhao, Haoyu Chen, Cong Ren, Bin Guo

“…To better explore and perfect the mechanism of action of artemisinin in ophthalmic diseases, and to better promote the clinical application of artemisinin, this study reviews the latest progress of artemisinin treatment for uveitis, uveal melanoma, age-related macular degeneration, diabetic retinopathy, ocular neovascularization, and dry eye, and it will provide theoretical support for the large-scale application of artemisinin in ophthalmic diseases in the future.…”
Get full text

Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy by Yue Wang, Kevin Chang, Aslan Mansurov, Jun Ishihara, Seounghun Kang, Trevin Kurtanich, Hye Rin Chun, Anna J Slezak, Lisa R Volpatti, Thomas Wang, Aaron T Alpar, Kirsten C Refvik, O Isabella Hansen, Gustavo J Borjas, Brendan T K Berg, Ha-Na Shim, Kevin T Hultgren, Suzana Gomes, Ani Solanki, Melody A Swartz, Jeffrey A Hubbell

“…The combination therapy also improved the efficacy of CPI in a CPI-resistant genetically-engineered melanoma model and exhibited synergistic antitumor efficacy in a pulmonary metastasis model.Conclusion Our strategy provides a rational design for combination immunotherapy targeting both myeloid and lymphoid compartments through complementary mechanisms.…”
Get full text

CD4 T cell depletion increases memory differentiation of endogenous and CAR T cells and enhances the efficacy of Super2 and IL-33-armored CAR T cells against solid tumors by Chrystal Paulos, Mary Jo Turk, Megen C Wittling, Yina H Huang, Asmaa O Mohamed, David Tyler Boone, Shannon L Ferry, Melanie C Peck, Alicia M Santos, Haille E Soderholm

“…Here, we describe the intrinsic ability of CAR T cells to differentiate into memory T cells, the effect of cytokine armoring, and neoadjuvant CD4 depletion therapy on CAR and tumor-specific endogenous memory T cells.Methods TRP1-specific or NKG2D CAR T cells alone or with Super2+IL-33 (S233) armoring and/or CD4 depletion were evaluated in immunocompetent B16F10 melanoma or MC38 colon cell carcinoma models without preconditioning. …”
Get full text

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme by Peter Nash, Yoshiya Tanaka, Kevin L Winthrop, Eun Bong Lee, Xavier Mariette, Jeffrey R Curtis, Kenneth Kwok, Connie Chen, Pinaki Biswas, Lisy Wang, Christina Charles-Schoeman, Ann Madsen, Stanley B Cohen, Andrea Shapiro, Jürgen Wollenhaupt

“…IRs (95% CI) for malignancies (excluding non-melanoma skin cancer [NMSC]), NMSC and lymphomas were 0.8 (0.7 to 0.9), 0.6 (0.5 to 0.7) and 0.1 (0.0 to 0.1), respectively. …”
Get full text

Development of a new nanobiotechnology method for the differential diagnosis of ocular adnexal tumors by S.V. Saakyan, D.A. Skladnev, A.P. Alekseeva, O.V. Beznos, V.V. Sorokin

“…Among the malignant conjunctival tumors, melanoma is characterized by the highest reducibility p&lt;0.05). …”
Get full text